GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Shyndec Pharmaceutical Co 600420.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.24

-0.60%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥9.36bn

FY2016FY2025

Net income

CN¥944.4m

FY2016FY2025

Free cash flow

CN¥1.43bn

FY2016FY2025

Shareholders' equity

CN¥15.70bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥9.36bnCN¥10.94bnCN¥12.07bnCN¥12.96bnCN¥13.94bnCN¥12.56bnCN¥12.20bnCN¥11.32bnCN¥8.52bnCN¥9.13bn
Research and developmentCN¥441.8mCN¥598.1mCN¥569.4mCN¥520.9mCN¥589.2mCN¥498.9mCN¥417.2mCN¥373.6mCN¥319.2mCN¥365.3m
Operating incomeCN¥1.31bnCN¥1.75bnCN¥1.08bnCN¥1.02bnCN¥964.9mCN¥1.12bnCN¥1.18bnCN¥1.47bnCN¥1.16bnCN¥898.4m
Net incomeCN¥944.4mCN¥1.08bnCN¥691.9mCN¥627.8mCN¥568.3mCN¥648.8mCN¥656.4mCN¥705.5mCN¥515.8mCN¥476.9m
Diluted earnings per share0.700.810.520.540.550.550.520.670.470.30

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥19.23bnCN¥19.96bnCN¥19.35bnCN¥19.63bnCN¥19.07bnCN¥18.25bnCN¥17.64bnCN¥16.46bnCN¥15.17bnCN¥15.02bn
Cash and short-term investmentsCN¥4.14bnCN¥7.64bnCN¥5.97bnCN¥6.15bnCN¥4.28bnCN¥3.72bnCN¥5.16bnCN¥3.83bnCN¥2.44bnCN¥1.64bn
Total liabilities−CN¥15.70bnCN¥4.63bnCN¥5.01bnCN¥7.48bnCN¥8.70bnCN¥8.43bnCN¥8.44bnCN¥8.02bnCN¥7.52bnCN¥8.08bn
Debt—CN¥1.74bnCN¥1.13bnCN¥3.40bnCN¥3.58bnCN¥3.15bnCN¥4.30bnCN¥3.73bnCN¥4.10bnCN¥4.94bn
Shareholders' equityCN¥15.70bnCN¥13.20bnCN¥12.39bnCN¥10.31bnCN¥8.59bnCN¥8.13bnCN¥7.59bnCN¥6.81bnCN¥6.17bnCN¥5.70bn
Shares outstanding1,342m1,341m1,341m1,166m1,027m1,177m1,252m1,056m1,107m1,600m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.70bnCN¥2.26bnCN¥1.72bnCN¥2.86bnCN¥1.68bnCN¥1.56bnCN¥1.27bnCN¥1.67bnCN¥2.31bnCN¥838.6m
Capital spending−CN¥263.8m−CN¥219.8m−CN¥357.2m−CN¥307.4m−CN¥521.4m−CN¥378.0m−CN¥403.8m−CN¥399.4m−CN¥168.4m−CN¥241.3m
Free cash flowCN¥1.43bnCN¥2.04bnCN¥1.36bnCN¥2.55bnCN¥1.16bnCN¥1.18bnCN¥866.3mCN¥1.27bnCN¥2.15bnCN¥597.3m
Dividends paid−CN¥427.9m−CN¥300.7m−CN¥189.4m−CN¥102.7m−CN¥212.5m−CN¥102.7m−CN¥105.6m−CN¥456.9m−CN¥395.8m−CN¥467.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.88bnCN¥2.06bnCN¥2.44bnCN¥2.04bnCN¥2.27bnCN¥2.61bnCN¥2.34bnCN¥2.63bn
Operating incomeCN¥194.9mCN¥257.5mCN¥212.6mCN¥183.5mCN¥411.1mCN¥509.1mCN¥283.6mCN¥371.7m
Net incomeCN¥137.2mCN¥138.4mCN¥143.2mCN¥129.1mCN¥310.7mCN¥361.4mCN¥129.1mCN¥236.0m
Diluted earnings per share0.100.100.110.100.230.270.100.18
Cash from operations———CN¥486.0mCN¥363.0mCN¥304.0mCN¥229.0mCN¥209.0m
Capital spending−CN¥52.0m−CN¥56.0m−CN¥57.0m−CN¥67.0m−CN¥86.0m−CN¥52.0m−CN¥63.0m−CN¥45.0m
Free cash flow———CN¥419.0mCN¥277.0mCN¥252.0mCN¥166.0mCN¥164.0m
Total assetsCN¥19.37bnCN¥19.46bnCN¥19.23bnCN¥19.33bnCN¥19.67bnCN¥19.33bnCN¥19.96bnCN¥20.07bn
Cash and short-term investments——CN¥4.14bnCN¥4.14bnCN¥6.46bnCN¥5.11bnCN¥7.64bnCN¥5.64bn
Debt———CN¥1.14bnCN¥30.0mCN¥769.0mCN¥50.1mCN¥50.1m
Shareholders' equityCN¥13.79bnCN¥13.92bnCN¥15.70bnCN¥13.64bnCN¥13.64bnCN¥13.57bnCN¥13.20bnCN¥13.07bn

Financial ratios

Data as of 1 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin14.0%16.0%9.0%7.9%6.9%8.9%—
Net margin10.1%9.9%5.7%4.8%4.1%5.2%—
Return on equity6.0%8.2%5.6%6.1%6.6%8.0%—
Return on assets4.9%5.4%3.6%3.2%3.0%3.6%—
Free cash flow yield17.4%22.0%18.5%32.3%25.6%19.6%—
Revenue growth-14.4%-9.4%-6.9%-7.1%11.1%2.9%—
Earnings growth-12.8%56.6%10.2%10.5%-12.4%-1.2%—
Current ratio3.59x2.69x2.82x2.78x1.59x1.64x—
Debt to equity—0.12x0.09x0.32x0.41x0.47x0.46x
Equity ratio81.6%66.2%64.0%52.5%45.1%44.6%—
Interest coverage299.62x45.04x17.45x9.13x8.74x8.42x—
R&D as a share of sales4.7%5.5%4.7%4.0%4.2%4.0%—
Buybacks as a share of market value-0.1%0.0%-15.1%-13.5%12.8%6.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-10.3%-5.7%0.4%
Operating income8.9%3.2%2.9%
Net income14.6%7.8%5.9%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin15.1%11.4%10.1%10.6%
Net margin10.0%7.4%6.4%6.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings14.314.819.016.918.717.317.113.727.355.6
Price to sales1.41.51.10.80.80.90.90.81.62.9

Dividends and splits

Per share, in the currency the company pays

Paid for 11 years. Last went ex-dividend on 3 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.200.300.200.100.100.100.100.10
  • 2-for-1 split · 25 May 2017
  • 11-for-10 split · 11 Apr 2008
  • 2-for-1 split · 25 May 2006
  • 1-to-1 reverse split · 4 Apr 2006
  • 3-for-2 split · 15 Jun 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.